Pharmaceutical compositions based on NK2 antagonists for pediatric use

Abstract

Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.

1 - 20 . (canceled) 
   
   
       21 . Oral pharmaceutical compositions for paediatric use comprising a tachykinin antagonist in the form of paediatric drops or syrup wherein the tachykinin antagonist is a NK2 antagonist chosen from the group consisting of:
 cyclo((Asn(β-D-2-deoxy-2-acetamido-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2β-5β)),   cyclo((Asn(β-D-galactopyranosyl)-Asp-Trp-Phe-Dap-Leu)cyclo(2β-5β)),   cyclo((Asn(4-O-(α-DGlc)-β-D-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2β-5β)),   cyclo((Dap(lactobionyl)-Asp-Trp-Phe-Dap-Leu)cyclo(2β-5β)).   
   
   
       22 . Pharmaceutical compositions as claimed in  claim 21  wherein the NK2 antagonist is cyclo((Asn(β-D-2-deoxy-2-acetamido-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2β-5β)). 
   
   
       23 . Pharmaceutical compositions as claimed in  claim 21  wherein the tachykinin antagonist is present in a concentration of 0.01 to 50 mg/ml. 
   
   
       24 . Pharmaceutical compositions as claimed in  claim 21  wherein the tachykinin antagonist is present in a concentration of 0.1 to 10 mg/ml. 
   
   
       25 . Foods for feeding an infant comprising a pharmaceutical composition according to  claim 21 . 
   
   
       26 . Foods according to  claim 25 , wherein such food is milk.